A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole
about
Comparative lipidomics in clinical isolates of Candida albicans reveal crosstalk between mitochondria, cell wall integrity and azole resistanceGlobal analysis of the evolution and mechanism of echinocandin resistance in Candida glabrataInhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole ResistanceMitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in FungiAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisXenobiotic efflux in bacteria and fungi: a genomics updateInhibition of electron transport chain assembly and function promotes photodynamic killing of Candida.Azole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants.The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.Determination of antifungal susceptibility patterns among the clinical isolates of Candida speciesMitochondrial sorting and assembly machinery subunit Sam37 in Candida albicans: insight into the roles of mitochondria in fitness, cell wall integrity, and virulenceActivity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.In search of the holy grail of antifungal therapyStimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilmsHypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicansMitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy.A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata.Mitochondria influence CDR1 efflux pump activity, Hog1-mediated oxidative stress pathway, iron homeostasis, and ergosterol levels in Candida albicans.Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Identification and Characterization of Key Charged Residues in the Cofilin Protein Involved in Azole Susceptibility, Apoptosis, and Virulence of Aspergillus fumigatus.Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral c
P2860
Q28480747-0C648469-F7B9-41E3-897C-69137154041FQ28483785-CA15FA4A-A5CA-491A-AAAB-D4A2976C2EF8Q28547078-4D412678-4FD8-468A-9CEB-36A620E4C12CQ28552733-2FA9805F-7CBE-4245-AE39-517A664C0855Q28818603-7C070339-49BA-409F-A212-FBF7692349F1Q28834633-82363706-73E4-4E98-94E7-1C1536C5BE3AQ33895907-0B0A6343-2A3D-45F9-B13E-D61DEC157794Q34475368-60C4CB1E-08B1-4BFD-BD7D-4095D3555F3CQ34597385-C3D7FC63-EE57-4F82-856C-004EECE8926CQ35646997-EA4C5EE5-8B23-481D-BEAF-AFA5953A4290Q35867270-A8DD6ACF-72BD-4BC8-832B-18EDF6230FF8Q36439061-20238291-3EA7-4663-AC25-D256456E12B0Q36672181-5FA6F517-01FB-46BC-B435-879A2E7B14E1Q36974985-137AA5BE-48CD-4384-A4CB-59317BAC687CQ37247798-202362AB-1113-4CD3-AC04-C599774C233BQ37417553-EE2B766A-B451-4C17-94B7-701570BC44F5Q37934279-C5AA393A-6E90-4493-9696-FAB957D983EAQ41774705-0B4376C8-A32B-473D-BFC8-1D93CDD67F3CQ41789295-BE8F1C26-692F-499F-B602-15D831FD2334Q43211026-AF73A31B-7594-4D3F-AA28-BF00195B7877Q44273424-6CBBB258-E84A-4D54-9701-AC0360FC6542Q52684508-150B953E-D9F8-44A7-B26F-709D883F8178Q58490188-83B1663E-F45D-40F4-8222-D09EE5667CAC
P2860
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A Candida albicans petite muta ...... o fluconazole and voriconazole
@ast
A Candida albicans petite muta ...... o fluconazole and voriconazole
@en
type
label
A Candida albicans petite muta ...... o fluconazole and voriconazole
@ast
A Candida albicans petite muta ...... o fluconazole and voriconazole
@en
prefLabel
A Candida albicans petite muta ...... o fluconazole and voriconazole
@ast
A Candida albicans petite muta ...... o fluconazole and voriconazole
@en
P2093
P2860
P356
P1476
A Candida albicans petite muta ...... o fluconazole and voriconazole
@en
P2093
Cornelius J Clancy
Katherine T Nguyen
M Hong Nguyen
Shaoji Cheng
William Clapp
P2860
P304
P356
10.1128/AAC.00182-07
P407
P577
2007-02-26T00:00:00Z